Sara M Mangsbo
Overview
Explore the profile of Sara M Mangsbo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
988
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kerzeli I, Lord M, Doroszko M, Elgendy R, Chourlia A, Stepanek I, et al.
PLoS One
. 2021 Jul;
16(7):e0253178.
PMID: 34232958
Bladder cancer, one of the most prevalent malignancies worldwide, remains hard to classify due to a staggering molecular complexity. Despite a plethora of diagnostic tools and therapies, it is hard...
12.
van Hooren L, Vaccaro A, Ramachandran M, Vazaios K, Libard S, van de Walle T, et al.
Nat Commun
. 2021 Jul;
12(1):4127.
PMID: 34226552
Gliomas are brain tumors characterized by an immunosuppressive microenvironment. Immunostimulatory agonistic CD40 antibodies (αCD40) are in clinical development for solid tumors, but are yet to be evaluated for glioma. Here,...
13.
Eltahir M, Isaksson J, Mattsson J, Karre K, Botling J, Lord M, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34206510
Checkpoint inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC). However, only a minority of patients demonstrate a durable clinical response. PD-L1 scoring is currently the...
14.
Havervall S, Rosell A, Phillipson M, Mangsbo S, Nilsson P, Hober S, et al.
JAMA
. 2021 Apr;
325(19):2015-2016.
PMID: 33825846
No abstract available.
15.
Georganaki M, Ramachandran M, Tuit S, Gonzalo Nunez N, Karampatzakis A, Fotaki G, et al.
Oncoimmunology
. 2020 Apr;
9(1):1730538.
PMID: 32231867
CD40-stimulating immunotherapy can elicit potent anti-tumor responses by activating dendritic cells and enhancing T-cell priming. Tumor vessels orchestrate T-cell recruitment during immune response, but the effect of CD40-stimulating immunotherapy on...
16.
Fletcher E, van Maren W, Cordfunke R, Dinkelaar J, Codee J, van der Marel G, et al.
J Immunol
. 2018 May;
201(1):87-97.
PMID: 29752315
Enhancing T cell responses against both viral and tumor Ags requires efficient costimulation and directed delivery of peptide Ags into APCs. Long peptide vaccines are considered favorable vaccine moieties from...
17.
Mangsbo S, Fletcher E, van Maren W, Redeker A, Cordfunke R, Dillmann I, et al.
Mol Immunol
. 2017 Nov;
93:115-124.
PMID: 29175591
Immune complexes are potent mediators of cellular immunity and have been extensively studied for their disease mediating properties in humans and for their role in anti-cancer immunity. However, a viable...
18.
Irenaeus S, Schiza A, Mangsbo S, Wenthe J, Eriksson E, Krause J, et al.
Oncotarget
. 2017 Nov;
8(45):78573-78587.
PMID: 29108250
Background: AdCD40L is an immunostimulatory gene therapy under evaluation for advanced melanoma, including ocular melanoma. Herein, we present the final data of a Phase I/IIa trial using AdCD40L alone or...
19.
Fletcher E, Eltahir M, Lindqvist F, Rieth J, Tornqvist G, Leja-Jarblad J, et al.
Int Immunopharmacol
. 2017 Nov;
54:1-11.
PMID: 29100032
First infusion reactions along with severe anaphylactic responses can occur as a result of systemic administration of therapeutic antibodies. The underlying mechanisms by which monoclonal antibodies induce cytokine release syndrome...
20.
van Hooren L, Sandin L, Moskalev I, Ellmark P, Dimberg A, Black P, et al.
Eur J Immunol
. 2016 Nov;
47(2):385-393.
PMID: 27873300
Checkpoint blockade of CTLA-4 results in long-lasting survival benefits in metastatic cancer patients. However, patients treated with CTLA-4 blockade have suffered from immune-related adverse events, most likely due to the...